StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a report issued on Wednesday morning. The brokerage issued a sell rating on the biotechnology company's stock.

Separately, Barclays dropped their price objective on Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th.

Cellectis Trading Down 8.1 %

NASDAQ:CLLS traded down $0.17 on Wednesday, reaching $1.93. The company's stock had a trading volume of 210,196 shares, compared to its average volume of 372,439. The firm has a market cap of $107.28 million, a price-to-earnings ratio of -1.48 and a beta of 3.08. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 12-month low of $1.41 and a 12-month high of $3.38. The stock has a 50 day moving average price of $1.84 and a 200 day moving average price of $2.01.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million for the quarter, compared to analysts' expectations of $5.00 million. During the same period last year, the business earned ($0.31) EPS. On average, equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CLLS. Principal Financial Group Inc. lifted its position in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock worth $817,000 after purchasing an additional 12,467 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Cellectis in the 2nd quarter valued at about $29,000. First Affirmative Financial Network acquired a new stake in Cellectis during the third quarter worth approximately $45,000. Finally, Long Focus Capital Management LLC lifted its position in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after buying an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.